Entolimod (CBLB502) is being developed by Cleveland Biolabs, Inc. for dual indications under the U.S. Food & Drug Administration’s (FDA) Animal Efficacy Rule as a pivotal-stage radiation countermeasure, and under the FDA’s traditional drug approval pathway as a targeted cancer treatment. Entolimod is an engineered derivative of the Salmonella flagellin protein that induces a spectrum of protective effects upon direct interaction and signaling via toll-like receptor 5 (TLR5).
The FDA established the Animal Efficacy Rule in 2002 to permit the approval of certain drugs and biologics that are intended to reduce or prevent serious or life threatening conditions based on evidence of safety from trial in healthy subjects and effectiveness from appropriate animal studies when human efficacy studies are not ethical or feasible. Efficacy of Entolimod as a radiation countermeasure has been assessed in animal models. These studies demonstrate that a single administration of Entolimod given either before or after lethal total body irradiation leads to significant improvement in animal survival. Entolimod has been shown to reduce radiation damage to both hematopoietic (HP) and gastrointestinal (GI) tissues and improve tissue regeneration. Two clinical studies that involved administration of a range of doses of Entolimod in 150 healthy human subjects have been completed. Both studies demonstrated that administration of Entolimod appears to be safe within a certain dose range. The most frequent adverse event associated with Entolimod administration was a transient flu-like syndrome, which is consistent with the mechanism of action of the compound. Ongoing studies will enable accurate definition of the projected human efficacious dose based on comparison of biomarker responses in humans and in animals. A few additional animal and human studies need to be completed prior to submitting a Biological License Application (BLA) for licensure with the FDA. The protocols for these remaining studies are being discussed with the FDA. The FDA granted Entolimod both Fast Track and Orphan Drug status for reducing the risk of death following a potentially lethal dose of total body irradiation during or after a radiation disaster. The U.S. government provides funding to conduct biodefense research and support the development of drugs and vaccines as medical countermeasures against potential terrorist attacks. Both the Department of Health and Human Services and the Department of Defense procure and maintain medical stockpiles to respond to bioterrorist and emerging infectious disease outbreaks. Under a declared state of emergency, countermeasures may be procured for the Strategic National Stockpile under an Emergency Use Authorization prior to their full FDA licensure approval.
Preclinical studies have shown that Entolimod has a suppressive effect on growth of TLR5 expressing tumors. Entolimod has also been shown to have an effect on several animal models of liver metastasis, regardless of TLR5 expression. Additionally, Entolimod evidences a supportive care benefit in preclinical models when combined with radiation treatment and cytotoxic agents with adverse gastrointestinal (GI) effects. Tissue protective effects of TLR5 agonists are limited to normal tissues and do not involve protection of tumors from treatment. A Phase I advanced solid tumor study is currently ongoing at Roswell Park Cancer Institute. The Principal Investigator for this trial is Alex Adjei, M.D., Ph.D., FACP, Chair of the Department of Medicine and Senior Vice President of Clinical Research at Roswell Park Cancer Institute. For more information on this trial, please refer to Clinicaltrial.gov: http://clinicaltrial.gov/ct2/show/NCT01527136?term=196111&rank=1. Additionally, Entolimod may also be developed as an adjuvant to standard radiation and chemotherapy, which will allow using of more aggressive measures to attack malignant cells and increase the effectiveness of cancer treatment.
- Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV. 2013. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proceedings of the National Academy of Science. 2013 May 14;110(20):E1857-66. doi: 10.1073/pnas.1222805110. Epub 2013 Apr 29. (PMID 23630282)
- Ding X, Bian G, Leigh ND, Qiu J, McCarthy PL, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X., 2012. A TLR5 Agonist Enhances CD8+ T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease. J Immunol 189(10):4719-4727. doi: 10.4049/jimmunol.1201206. Epub 2012 Oct 8 (PMID 23045613)
- Krivokrysenko V, Shakhov A, Singh V, Bone F, Kononov Y, Shyshynova I, Cheney A, Maitra R, Purmal A, Whitnall M, Gudkov AV, Feinstein E., 2012. Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. Journal Pharmacology and Experimental Therapeutics July 26 (e-pub ahead of print) (PMID 22837010)
- Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA., 2012. Structural Basis of TLR5-Flagellin Recognition and Signaling. Science 335:859-864 (PMID 22344444)
- Mueller, K., 2012. Flagellin Takes Its Toll. Science. Editor's Choice 5:212 p ec62
- Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV., 2011. Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy. International Journal of Radiation Oncology, Biology and Physics, Oct.14 (e-pub ahead of print) (PMID 22000579)
- Fukuzawa N, Petro M, Baldwin WM 3rd, Gudkov AV, Fairchild RL., 2011. A TLR5 agonist inhibits acute renal ischemic failure. Journal of Immunology 187: 3831-3839 (PMID 21890657)
- Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV., 2008. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320:226-230 (PMID 18403709)
- Lu J., Sun PD. 2012. The Structure of the TLR5-Flagellin Complex: A New Mode of Pathogen Detection, Conserved Receptor Dimerization for Signaling. Science Signaling 5, (pe 11) (PMID 22434932)
- Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D., 2011. Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth. Cancer Research DOI:10.1158/0008-5472.CAN-10-1993 (PMID 21427357)
- Bhattacharjee, Y. 2008. Medicine. Drug bestows radiation resistance on mice and monkeys. Science 320:163 (PMID 18403680)